Trial Profile
Personalized therapy for pazopanib by pharmacokinetic analysis in patients with renal cell carcinoma or malignant soft tissue tumor
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Sep 2022
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2018 New trial record